508 related articles for article (PubMed ID: 29496649)
21. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Fahmy O; Khairul-Asri MG; Schubert T; Renninger M; Malek R; Kübler H; Stenzl A; Gakis G
Urol Oncol; 2018 Feb; 36(2):43-53. PubMed ID: 29102254
[TBL] [Abstract][Full Text] [Related]
22. Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes.
Ma B; Li H; Zhang C; Yang K; Qiao B; Zhang Z; Xu Y
Eur J Surg Oncol; 2013 Oct; 39(10):1150-6. PubMed ID: 23721764
[TBL] [Abstract][Full Text] [Related]
23. Comparative survival analysis of bladder preservation therapy versus radical cystectomy in muscle-invasive bladder cancer.
Kang NW; Feng YH; Lin KL; Chen YC; Ho CH; Yang CC
Cancer Med; 2024 Jan; 13(2):e6972. PubMed ID: 38379322
[TBL] [Abstract][Full Text] [Related]
24. Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis.
Schuettfort VM; Pradere B; Quhal F; Mostafaei H; Laukhtina E; Mori K; Sari Motlagh R; Fisch M; D'Andrea D; Rink M; Gontero P; Soria F; Shariat SF
World J Urol; 2021 Jun; 39(6):1757-1768. PubMed ID: 32995918
[TBL] [Abstract][Full Text] [Related]
25. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K
BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
[TBL] [Abstract][Full Text] [Related]
26. Significance of preoperative butyrylcholinesterase as an independent predictor of survival in patients with muscle-invasive bladder cancer treated with radical cystectomy.
Koie T; Ohyama C; Yamamoto H; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Kitayam M; Hirota K
Urol Oncol; 2014 Aug; 32(6):820-5. PubMed ID: 24951323
[TBL] [Abstract][Full Text] [Related]
27. Comparison of survival outcomes between primary and secondary muscle-invasive bladder cancer: An updated meta-analysis.
Zheng X; Qiu S; Yang L; Wei Q
Int J Med Sci; 2021; 18(2):505-510. PubMed ID: 33390819
[No Abstract] [Full Text] [Related]
28. Survival after Radical Cystectomy for Bladder Cancer in Relation to Prior Non-Muscle Invasive Disease in Quebec.
Zakaria AS; Santos F; Kassouf W; Tanguay S; Aprikian A
Urol Int; 2016; 97(1):49-53. PubMed ID: 26863611
[TBL] [Abstract][Full Text] [Related]
29. Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle-invasive bladder cancer.
Ritch CR; Balise R; Prakash NS; Alonzo D; Almengo K; Alameddine M; Venkatramani V; Punnen S; Parekh DJ; Gonzalgo ML
BJU Int; 2018 May; 121(5):745-751. PubMed ID: 29281848
[TBL] [Abstract][Full Text] [Related]
30. Risk factors and oncological outcomes of urethral recurrence in male patients with muscle invasive bladder cancer after radical cystectomy combined with urinary diversion: a propensity score-matched case control study.
Yao Z; Jiang Y; Zhu X; Wu B; Bai S
Int J Clin Oncol; 2020 Jul; 25(7):1377-1384. PubMed ID: 32318904
[TBL] [Abstract][Full Text] [Related]
31. Chemoradiation Vs Radical Cystectomy for Muscle-invasive Bladder Cancer: A Propensity Score-weighted Comparative Analysis Using the National Cancer Database.
Kaushik D; Wang H; Michalek J; Liss MA; Liu Q; Jha RP; Svatek RS; Mansour AM
Urology; 2019 Nov; 133():164-174. PubMed ID: 31401220
[TBL] [Abstract][Full Text] [Related]
32. miR-199a-3p and miR-214-3p improve the overall survival prediction of muscle-invasive bladder cancer patients after radical cystectomy.
Ecke TH; Stier K; Weickmann S; Zhao Z; Buckendahl L; Stephan C; Kilic E; Jung K
Cancer Med; 2017 Oct; 6(10):2252-2262. PubMed ID: 28879675
[TBL] [Abstract][Full Text] [Related]
33. Use of preoperative performance status and hemoglobin concentration to predict overall survival for patients aged ≥ 75 years after radical cystectomy for treatment of bladder cancer.
Hara T; Matsuyama H; Kamiryo Y; Hayashida S; Yamamoto N; Nasu T; Joko K; Baba Y; Suga A; Yamamoto M; Aoki A; Takai K; Yoshihiro S; Konishi M; Sakano S; Imoto K; Tei Y; Yamaguchi S; Yano S;
Int J Clin Oncol; 2016 Feb; 21(1):139-47. PubMed ID: 26077140
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of lymphovascular invasion in bladder cancer after surgical resection: A meta-analysis.
Tian YF; Zhou H; Yu G; Wang J; Li H; Xia D; Xiao HB; Liu JH; Ye ZQ; Xu H; Zhuang QY
J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):646-655. PubMed ID: 26489616
[TBL] [Abstract][Full Text] [Related]
35. Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making.
Aziz A; Shariat SF; Roghmann F; Brookman-May S; Stief CG; Rink M; Chun FK; Fisch M; Novotny V; Froehner M; Wirth MP; Schnabel MJ; Fritsche HM; Burger M; Pycha A; Brisuda A; Babjuk M; Vallo S; Haferkamp A; Roigas J; Noldus J; Stredele R; Volkmer B; Bastian PJ; Xylinas E; May M
BJU Int; 2016 Feb; 117(2):272-9. PubMed ID: 25381844
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer: A retrospective multicenter study.
Orré M; Latorzeff I; Fléchon A; Roubaud G; Brouste V; Gaston R; Piéchaud T; Richaud P; Chapet O; Sargos P
PLoS One; 2017; 12(4):e0174978. PubMed ID: 28384195
[TBL] [Abstract][Full Text] [Related]
37. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients.
Koga F; Kihara K; Yoshida S; Yokoyama M; Saito K; Masuda H; Fujii Y; Kawakami S
BJU Int; 2012 Mar; 109(6):860-6. PubMed ID: 21854531
[TBL] [Abstract][Full Text] [Related]
38. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
[TBL] [Abstract][Full Text] [Related]
39. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
[TBL] [Abstract][Full Text] [Related]
40. Primary versus secondary muscle-invasive bladder cancer: survival after curative treatment.
Møller CT; Fosså SD; Tafjord G; Babigumira R; Berge V; Andreassen BK
Scand J Urol; 2022 Jun; 56(3):214-220. PubMed ID: 35506475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
